Pathway Bioventures

Axonis Therapeutics is a biotechnology company focused on neurological disorders. It develops medicines targeting KCC2, a critical mediator of inhibition within the brain, using a proprietary neuron-specific K-Cl cotransporter (KCC2) discovery engine. The company aims to improve lives by treating conditions such as epilepsy and pain.

Modifi Bio develops oncology therapeutics based on direct DNA modification. The company pursues a platform that modifies tumor DNA to render cancer cells irreparable while preserving healthy cells, aiming to disrupt conventional oncology drug development.

Afference specializes in wearable electronics, focusing on innovative technologies that bridge the gap between digital and physical experiences. Their core product enables users to interact with various devices such as VR, AR, and gaming consoles through advanced neural stimulation, providing tactile feedback.

IpiNovyx Bio is a biopharmaceutical company focused on creating a novel platform of immunoproteasome-modulating therapeutics aimed at improving the treatment of autoimmune and inflammatory diseases. The company's innovative approach involves developing inhibitors that selectively target the immunoproteasome, which plays a critical role in regulating specific immune cell types. By modulating these immune responses, IpiNovyx Bio seeks to enable patients to recover more effectively from their conditions and enhance their overall health.

miRecule is a biotechnology company developing targeted RNA therapies for cancer and muscular dystrophy. It uses its proprietary DREAmiR platform to analyze genomic data from thousands of patients, identifying genetic abnormalities and creating tailored RNA therapeutics to directly address these issues.

CytoVale is a medical technology company based in San Francisco that develops biomarkers derived from the mechanical properties of single cells. The company uses microfluidics to route and probe cells, enabling the measurement of multiple biophysical indicators at once. Its technology aims to advance early detection of immune-mediated diseases and sepsis through the analysis of cell mechanics and machine learning. By translating biophysical signals into diagnostic information, CytoVale seeks to improve diagnostic accuracy, support timely treatment decisions, and reduce healthcare costs.

Dimension Inx designs and develops advanced biomaterials for regenerative medicine. Founded in 2017, it specializes in creating microenvironments that guide the body's natural healing processes. Its platform focuses on the interplay between material composition, microstructure, and microarchitecture to produce biofunctional materials.

miRecule is a biotechnology company developing targeted RNA therapies for cancer and muscular dystrophy. It uses its proprietary DREAmiR platform to analyze genomic data from thousands of patients, identifying genetic abnormalities and creating tailored RNA therapeutics to directly address these issues.

Simergent, LLC is a manufacturer of automated peritoneal dialysis devices, established in 2014 and headquartered in Oklahoma City, Oklahoma, with an additional presence in Chicago, Illinois. The company focuses on developing affordable home dialysis solutions for both developed and emerging markets. Its innovative device is designed to be cost-effective and user-friendly, featuring a disposable tubing set that operates independently to troubleshoot issues. This enables patients to maintain a normal lifestyle and engage socially with family and friends while undergoing treatment at home, thereby enhancing their quality of life.

Founded in 2017, Scioto Biosciences develops a platform for delivering live therapeutic bacteria directly to the gut. Its Activated Bacterial Therapeutics (ABT) platform enables bacteria to persist and adhere to intestinal mucosa, potentially treating various diseases associated with the gastrointestinal tract.